Semax

Overview

Semax is a synthetic heptapeptide based on a fragment of adrenocorticotropic hormone (ACTH 4-10), modified with a C-terminal Pro-Gly-Pro to extend its half-life. It is thought to act largely by upregulating BDNF and modulating monoaminergic signaling, without the hormonal (cortisol-releasing) activity of full ACTH. It was developed in Russia and is approved there for ischemic stroke and cognitive indications, but it is NOT FDA-approved in the US. Most of the supporting human data comes from Russian trials that have not been widely replicated by independent Western groups, so claims about cognitive enhancement in healthy people should be treated as preliminary and unproven.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Cognitive enhancement / focus in healthy users (marketed claim; human evidence limited and largely from Russia)
• Ischemic stroke recovery (approved use in Russia; not established to Western regulatory standards)
• Neuroprotection and mood support (marketed claim; not confirmed in independent controlled trials)

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Subjective — daily cognition, focus, and mood check-ins over a baseline period
• WHOOP — sleep stages and HRV trend, since stimulation/alertness effects are reported
• Subjective — anxiety and sleep-quality check-ins to catch overstimulation

Sources & References

1. [1]Semax — Wikipedia